Seeking Alpha

Intrexon completes acquisition of Medistem

  • Intrexon (XON) finalizes its buy of Medistem, a developer of endometrial regenerative cells (ERC). The company believes that ERCs can potentially be manufactured as genetically modified therapeutics delivery vehicles in the body.
  • 116 mutual funds have positions in the stock.
  • Press release
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: